key: cord-0687725-c79fbaeu authors: Westreich, Daniel; Edwards, Jessie K; Tennant, Peter W G; Murray, Eleanor J; van Smeden, Maarten title: Choice of Outcome in COVID-19 Studies and Implications for Policy: Mortality and Fatality date: 2021-10-06 journal: Am J Epidemiol DOI: 10.1093/aje/kwab244 sha: 159eff711a9ad5f113979785770b783b4a01ab9e doc_id: 687725 cord_uid: c79fbaeu In this brief communication, we discuss the confusion of mortality with fatality in the interpretation of evidence in the COVID-19 pandemic, and how this confusion affects the translation of science into policy and practice. We discuss how this confusion has influenced COVID-19 policy in France, Sweden, and the United Kingdom, and discuss the implications for decision-making about COVID-19 vaccine distribution. We also discuss how this confusion is an example of a more general statistical fallacy we term the "Missing Link Fallacy.” August 2020, the French government modified their definition of "vulnerable" to exclude various groups of people, including those with hypertension, chronic respiratory disease, and chronic cardiovascular disease. (1) In support, the French government cited a single study: Williamson et al. (2) , in which the authors took the primary care records of over 17 million adults in the United Kingdom, and linked those records to 10 (4) was subsequently changed in the most-recently updated version of (5); however, the overall reliance on (2) remains.) Suppose that -in the OpenSAFELY cohort -people with chronic respiratory disease were better at social distancing and/or self-isolating because of an enhanced fear of respiratory infection, and as a result were less likely to acquire SARS-CoV-2 and subsequently COVID-19 than others. Suppose this translated to an incidence risk 0.5 times the risk in those without chronic respiratory disease. Table 1 shows data consistent with this hypothetical. Now suppose this fear were justified, and that those infected with SARS-CoV-2 who had chronic respiratory disease were substantially more likely to die, specifically that these people had a risk of death 4 times the risk of death in those without chronic respiratory disease. Table 2 shows data consistent with this aspect of the scenario, concentrating only on those 95,000 individuals from Table 1 Making policy amidst a public health emergency, based on rapidly evolving evidence, is extremely challenging; we do not discount these challenges. Indeed we laud all policymakers who base their decisions on scientific evidence rather than on ideology. Nor must we let the perfect be the enemy of the good. When it comes to evidence, we can't always get what we want: but this is no excuse for complacency. Policy must be informed by appropriate evidence; poor or inapplicable evidence may not just be distracting or misleading, but it may be genuinely harmful. In particular, making policy based on confusing mortality with fatality could place the highest risk individuals at substantially increased risk of death, and must be avoided. More generally, we urge scientists to clarify the target populations to which their results apply and, where possible, to separate multi-stage outcomes such as mortality into distinct stages, such as incidence and fatality (17) . Regardless, scientists should aim to communicate more clearly and modestly about the policy implications of their results, and take time to consider and address the ways that they may be misinterpreted. More broadly, we note that the confusion of Pr( & ) and Pr( | ) represents a more general statistical fallacy, in the same way that that the assumption that Pr( | ) is equal to Pr( | ) (the Prosecutor's Fallacy (18) We emphasize that there is nothing wrong with mortality as an outcome per se; it may be precisely the right outcome to study when our goal is to prevent death overall or to target vaccination for the purpose of limiting transmissionrather than to target vaccinations to reduce the morbidity and mortality associated with infections specifically. Specifically, risk of infection may depend on behavior (as opposed to biology) to a greater extent than risk of death given infection, and thus may be more amenable to public health intervention (e.g., government financial support for staying at home); if the goal is reducing mortality in absence of vaccines, then it might be sensible to base policy on mortality. Rather, we urge policymakers to look more carefully at the outcomes being examined in studies that they are using to inform policy (e.g., (16) ), be alert for outcomes that inherently require one or more preconditions to be met, and consider the implications of the compound nature of those outcomes for the policies they are considering. Policymakers interested in factors that predispose to a higher risk of death in those infected with SARS-CoV-2, for example, should give preference to studies that focus on groups of infected individuals. BIGGEST TABLE 2 FALLACY EVER #EpiTwitter, do you remember the discussions around the @OpenSafely Williamson @nature study this summer? The French @gouvernementFR admitted they used this study's Table 2 to withdraw protections from 100.000s of workers at risk of severe #COVID19! Factors associated with COVID-19-related death using OpenSAFELY The French Supreme Court ruled in our favor, and overturned the government's decision, deeming it "neither coherent nor sufficiently justified": all the Vulnerables are once again protected! Thanks you all #EpiTwitter And thanks to @bengoldacre for his answer Information till riskgrupper om covid-19 COVID-19 Medical Risk Assessment The Quest for Timely Insights into COVID-19 Should not Come at the Cost of Scientific Rigor OpenSAFELY): The Table 2 Fallacy in a Study of COVID-19 Mortality Risk Factors The Authors Respond The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients Mortality, fatality, and morbidity (proper use of terms) Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study How CDC Is Making COVID-19 Vaccine Recommendations WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination Evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19 Target Validity and the Hierarchy of Study Designs Epidemiology visualized: the prosecutor's fallacy We are grateful to Dr. Stephen R. Cole for advice and comments on an earlier draft of this work.Author contributions: DW wrote the first draft; all authors reviewed all drafts and approved final submission.Conflict of interest: the authors declare no conflicts.